[Preclinical and clinical studies of the efficacy of Panavir in therapy for tick-borne encephalitis].

Abstract

The antiviral activity of Panavir was studied on a model of mice infected with the strain Sofjin of tick-borne encephalitis (TBE) virus. The efficacy of Panavir was studied in the treatment of the chronic (monotherapy; 30 patients) and acute febrile and meningeal (combined therapy; n = 113) forms of TBE. Panavir was found to have a positive effect on the clinical course of TBE and the immune mechanisms of the body's protection.

• Authors: A A Litvin, L I Ratnikova, P G Deriabin
• Journal: Voprosy virusologii (Vopr Virusol) 2009 May-Jun Vol. 54 Issue 3 Pg. 26-32 ISSN: 0507-4088 [Print] Russia (Federation)
• PMID: 19537094 (Publication Type: Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Antibodies, Viral
• Antigens
• Antioxidants
• Probucol

Topics

• Adult
• Aged
• Animals
• Animals, Newborn
• Antibodies, Viral (blood)
• Antigens (blood)
• Antioxidants (administration & dosage, therapeutic use)
• Drug Evaluation, Preclinical
• Encephalitis, Tick-Borne (blood, drug therapy, immunology)
• Female
• Humans
• Injections, Intravenous
• Lymphocyte Count
• Lymphocyte Subsets (immunology)
• Male
• Mice
• Middle Aged
• Probucol (administration & dosage, therapeutic use)
• Treatment Outcome